Posted by Michael Wonder on 22 Apr 2024
Carvykti (ciltacabtagene autoleucel) is the first BCMA targeted treatment approved by the European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy
22 April 2024 - Approval is based on results from the Phase 3 CARTITUDE-4 study, in which treatment with ciltacabtagene autoleucel in 1-3 prior lines of therapy reduced the risk of disease progression or death by 74 percent compared to standard therapies.
Janssen-Cilag announced today that the European Commission has approved a Type II variation for Carvykti (ciltacabtagene autoleucel).
